Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy - Jett Foundation
Sarepta Poised to Start Next Trial of SRP-9001 for Duchenne MD
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MO – Save Our Sons Duchenne Foundation
Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics' ELEVIDYS for Treatment of Duchenne Muscular Dystrophy | Muscular Dystrophy Association
Sarepta Therapeutics on X: "NEWS: SRPT today announced initiation and first patient dosed in the study known as VOYAGENE, a Ph 1 study of our investigational gene therapy for the treatment of
Hansa Biopharma on LinkedIn: Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a…
Sarepta Therapeutics Announces Clinical Hold on Micro-Dystrophin Gene Therapy Trial - Parent Project Muscular Dystrophy
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy - CureDuchenne
Sarepta Therapeutics | Une société biopharmaceutique dédiée aux maladies rares
Parent Project Muscular Dystrophy and Sarepta Therapeutics Partner to Launch Duchenne Outcomes Research Interchange, a Patient-Data Warehouse Serving the Entire Duchenne Community
Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial
In a U-turn, FDA orders AdComm for Sarepta's DMD gene therapy
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication - CureDuchenne
Sarepta and Catalent Expand Strategic Manufacturing Partnership with Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate | World Pharma Today
With FDA staff opposed to Sarepta therapy, top official intervened
Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
Sarepta Therapeutics - Yesterday, we announced that we have executed an exclusive license agreement for an investigational gene therapy candidate, calpain 3 (CAPN-3), to treat limb-girdle muscular dystrophy type 2A (LGMD2A), initially
News Archives - La Force dmd
Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA
Sarepta accepting applications for Route 79 scholarship program | Awards up to $5K will go to DMD patients and their siblings | Muscular Dystrophy News
Sarepta Announces Results From SRP-9001 Study - CureDuchenne
